Glucocorticoid receptor interactions with glucocorticoids: Evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants

Steroids

Volumn 68, Issue 4, 2003, Pages 329-339

  Hammer, Stefanie ^a   Spika, Irina ^a   Sippl, Wolfgang ^b   Jessen, Gisela ^b   Kleuser, Burkhard ^a   Höltje, Hans Dieter ^b   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glucocorticoid esters; Glucocorticoid receptor; Molecular modeling; Receptor binding; Receptor mutants; Steroid

Indexed keywords

AMINO ACID; ASPARAGINE; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; DESOXIMETASONE; DESOXIMETASONE 21 CINNAMATE; DEXAMETHASONE; ESTER; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LIGAND; MEDROXYPROGESTERONE ACETATE; METHIONINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE 17 PROPIONATE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; MUTANT PROTEIN; PREDNICARBATE; PREDNISOLONE; PREDNISOLONE 17 ETHYLCARBONATE; PREDNISOLONE 17 ETHYLCARBONATE 21 PHENYLACETATE; PREDNISOLONE 21 ETHYLCARBONATE; PROGESTERONE RECEPTOR; PROPIONIC ACID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANALYTICAL ERROR; ANIMAL CELL; ARTICLE; COMPUTER SIMULATION; CORRELATION COEFFICIENT; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; EVALUATION; FUNCTIONAL ASSESSMENT; GENE ACTIVATION; GENE TARGETING; HYDROGEN BOND; HYDROPHOBICITY; MEASUREMENT; METABOLITE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTANT; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; STANDARD; STEROID ANALYSIS; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 0037764882     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(03)00030-8     Document Type: Article

References (34)

1. Gysler A., Kleuser B., Sippl W., Lange K., Korting H.C., Höltje H.-D.et al. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm. Res. 16:1999;1386-1391.
2. Ponec M., Kempenaar J., Shroot B., Caron J.C. Glucocorticoids: binding affinity and lipophilicity. J. Pharm. Sci. 75:1986;973-975.
3. Pörtner M., Möllmann H., Rohdewald P. Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters. Pharm. Res. 5:1988;623-627.
4. Gysler A., Lange K., Korting H.C., Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 14:1997;793-797.
5. Barth J., Lehr K.H., Derendorf H., Möllmann H.W., Höhler T., Hochhaus G. Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Skin Pharmacol. 6:1993;179-186.
6. Lange K., Kleuser B., Gysler A., Bader M., Maia C., Scheidereit C.et al. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol. Appl. Skin Physiol. 13:2000;93-103.
7. Korting H.C., Unholzer A., Schäfer-Korting M., Tausch I., Gassmueller J., Nietsch K.H. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol. Appl. Skin Physiol. 15:2002;85-91.
8. Hanifin J., Abrams B., Cherill R. Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivative. J. Geriatr. Dermatol. 2:1994;119-127.
9. Schäfer-Korting M., Korting H.C., Kerscher M.J., Lenhard S. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin. Pharmacol. Ther. 54:1993;448-456.
10. Lange K., Gysler A., Bader M., Kleuser B., Korting H.C., Schäfer-Korting M. Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm. Res. 14:1997;1744-1749.
11. Spika I., Hammer S., Kleuser B., Korting H.C., Schäfer-Korting M. Transcriptional activity of potent glucocorticoids: relevance of glucocorticoid receptor isoforms and drug metabolites. Skin Pharmacol. Appl. Skin Physiol. 16:2003;143-150.
12. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D.et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110:2002;93-105.
13. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O.et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
14. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature. 393:1998;392-396.
15. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O.et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18:1999;4608-4618.
16. Lind U., Greenidge P., Gillner M., Koehler K.F., Wright A., Carlstedt-Duke J. Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J. Biol. Chem. 275:2000;19041-19049.
17. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R.et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 318:1985;635-641.
18. Danielsen M., Northrop J.P., Ringold G.M. The mouse glucocorticoid receptor: mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins. EMBO J. 5:1986;2513-2522.
19. Neumann J.R., Morency C.A., Russian K.O. A novel rapid assay for chloramphenicol acetyltransferase. Biotechniques. 5:1987;444-447.
20. Laskowski R.A. SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph. 13:1995;323-330.
21. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26:1993;283-291.
22. Nilsson J., Wikstrom H., Smilde A., Glase S., Pugsley T., Cruciani G.et al. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype. J. Med. Chem. 40:1997;833-840.
23. Sippl W. Receptor-based 3D QSAR analysis of estrogen receptor ligands - merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J. Comput. Aided Mol. Design. 14:2000;559-572.
24. Sippl W., Contreras J.M., Parrot I., Rival Y.M., Wermuth C.G. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J. Comput. Aided Mol. Design. 15:2001;395-410.
25. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S.et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9:2002;359-364.
26. Vayssiere B.M., Dupont S., Choquart A., Petit F., Garcia T., Marchandeau C.et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11:1997;1245-1255.
27. Wong C.W., Komm B., Cheskis B.J. Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry. 40:2001;6756-6765.
28. Kraichely D.M., Sun J., Katzenellenbogen J.A., Katzenellenbogen B.S. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 141:2000;3534-3545.
29. Steinmetz A.C., Renaud J.P., Moras D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 30:2001;329-359.
30. DiSorbo D., Rosen F., McPartland R.P., Milholland R.J. Glucocorticoid activity of various progesterone analogs: correlation between specific binding in thymus and liver and biologic activity. Ann. NY Acad. Sci. 286:1977;355-368.
31. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:1998;3317-3325.
32. Hellal-Levy C., Couette B., Fagart J., Souque A., Gomez-Sanchez C., Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 464:1999;9-13.
33. Marhefka C.A., Moore B.M. II, Bishop T.C., Kirkovsky L., Mukherjee A., Dalton J.T.et al. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44:2001;1729-1740.
34. Poujol N., Wurtz J.M., Tahiri B., Lumbroso S., Nicolas J.C., Moras D.et al. Specific recognition of androgens by their nuclear receptor. A structure-function study. J. Biol. Chem. 275:2000;24022-24031.